

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen J. Russell et al. Art Unit : 1646  
Serial No. : 10/756,818 Examiner : Unknown  
Filed : January 13, 2004  
Title : EXPRESSION OF IMMUNOGENIC SUBSTANCES

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

References are listed on the attached form PTO-1449. Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 09/197,056, filed on November 20, 1998. The following references were not submitted to and/or cited by the Office in the prior application and, therefore, are provided in this application:

Desig. IDs:

AG	Alvarez-Vallina, L., et al., "Delimitation of the Proliferative Stages in the Human Thymus Indicates that Cell Expansion Occurs before the Expression of CD3 (T Cell Receptor)," <u>J. Immunol.</u> , 1993, 150:8 16
AJJ	Patten et al., "Transfer of Putative Complementarity - Determining Region Loops of T Cell Receptor V Domains Confers Toxin Reactivity but not Peptide/MHC Specificity," <u>J. Immunol.</u> , 1992, 150:2281-2294

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. A check for \$180 in payment of the late submission fee of § 1.17(p) is enclosed.

The PTO did not receive the following listed items(s) FORs and NPLs

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

December 9, 2004

Signature

Debra L. MiedemaDebra L. Miedema

Typed or Printed Name of Person Signing Certificate

12/14/2004 SS1THIB1 00000018 10756818

01 FC:1806

180.00 00


Applicant : Stephen J. Russell et al.  
Serial No. : 10/756,818  
Filed : January 13, 2004  
Page : 2 of 2

Attorney's Docket No.: 07039-416002


Please apply any other charges or credits to Deposit Account No. 06 1050.

Respectfully submitted,

Date: December 9, 2004

  
\_\_\_\_\_  
J. Patrick Finn III, Ph.D.  
Reg. No. 44,109

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-416002	Application No. 10/756,818
		Applicant Stephen J. Russell et al.	
		Filing Date January 13, 2004	Group Art Unit 1646

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AA	WO 96/01313	01/18/1996	WIPO				
	AB	WO 96/40892	12/19/1996	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AC	Ackland-Berglund, C.E., et al., "Efficacy of tetracycline-controlled gene expression is influenced by cell type," <u>BioTechniques</u> , 1995, 18(2):196-200
	AD	Alvarez-Vallina, L., et al., "Antigen-specific targeting of CD28-mediated Tcell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors," <u>Eur. J. Immunol.</u> , 1996, 26:2304-2309
	AE	Alvarez-Vallina, L., "Pharmacological Control of Antigen Responsiveness in Genetically Modified T Lymphocytes," <u>J. Immunol.</u> , 1997
	AF	Alvarez-Vallina, L., et al., "Efficient Discrimination between Different Densities of Target Antigen by Tetracycline-Regulatable T Bodies," <u>Human Gene Therapy</u> , 1999, 10:559-563
	AG	Alvarez-Vallina, L., et al., "Delimitation of the Proliferative Stages in the Human Thymus Indicates that Cell Expansion Occurs before the Expression of CD3 (T Cell Receptor)," <u>J. Immunol.</u> , 1993, 150:8-16
	AH	Baron, U., et al., "Co-regulation of two gene activities by tetracycline via a bidirectional promoter," <u>Nucl. Acids Res.</u> , 1995, 23(17):3605-3606
	AI	Bell, S.J., et al., "Heterogeneous effects of exogenous IL-2 on HIV-specific cell-mediated immunity (CMI)," <u>Clin Exp. Immunol.</u> , 1992, 90(1):6-12
	AJ	Biron, C.A., "Cytokines in the generation of immune responses to, and resolution of, virus infection," <u>Curr. Opin. Immunol.</u> , 1994, 6:530-538
	AK	Brocker, T., et al., "Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor," <u>Eur. J. Immunol.</u> , 1996, 26(8):1770-1774
	AL	Cooke, Susan J., et al., "Regulated expression vectors demonstrate cell-type-specific sensitivity to human immunodeficiency virus type 1 Nef-induced cytoostasis," <u>J Gen Virol</u> , 1997, 78:381-392
	AM	Crystal, Ronald G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," <u>Science</u> , 1995, 270:404-410
	AN	Deonarain, Mahendra P., "Ligand-targeted receptor-mediated vectors for gene delivery," <u>Expert Opin. Ther. Pat.</u> , 1998, 8:53-69
	AO	Eshhar, Z., et al., "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the $\gamma$ or $\epsilon$ subunits of the immunoglobulin and T-cell receptors," <u>Proc. Natl. Acad. Sci. USA</u> , 90:720-724 (1993)
	AP	Floettmann, et al., "Cytostatic Effect of Epstein-Barr Virus Latent Membrane Protein-1 Analyzed Using Tetracycline-Regulated Expression in B Cell Lines," <u>Virology</u> , 223:29-40 (1996)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-416002	Application No. 10/756,818
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Stephen J. Russell et al.	
		Filing Date January 13, 2004	Group Art Unit 1646

(37 CFR §1.98(b))

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AQ	Gossen, M., et al. & Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," <u>Proc. Natl. Acad. Sci. USA</u> , 1992, 89:5547-5551
	AR	Gossen, M., et al., "Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements," <u>Trends Biol. Sci.</u> , 1993, 18:471-475
	AS	Hawkins et al., "Selection of phage antibodies by binding affinity. Mimicking affinity maturation," <u>J. Mol. Biol.</u> , 1992, 226:889-896
	AT	Hillen, W., et al., "Topics in Molecular and Structural Biology," <u>Protein-Nucleic Acid Interaction</u> , 1989, eds. Saenger & Heinemann, Macmillan, London, Vol. 10, pp 143-162
	AU	Hlavka, J.J., et al., "The Tetracyclines," 1985, <u>Handbook of Experimental Pharmacology</u> , 78, Blackwood et al, (eds.), Springer Verlag
	AV	Hoffman, A., et al., "Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette," <u>Proc. Natl. Acad. Sci. USA</u> , 1996, 93:5185-5190
	AW	Houin, G., et al., "The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man," <u>Br. J. Clin. Pharmacol.</u> , 1983, 16:245-252
	AX	Howe, J.R., et al., "The Responsiveness of a Tetracycline-sensitive Expression System Differs in Different Cell Lines," <u>J. Biol. Chem.</u> , 1995, 270:14168-14174
	AY	Hwu, P., et al., "Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain," <u>J. Exp. Med.</u> , 1993, 178:361-366
	AZ	Jiang, Wanping, et al., "The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing," <u>Nature</u> , 1995, 375:151-155
	AAA	Kloppenburger, M., et al., "The influence of tetracyclines on T cell activation," <u>Clin. Exp. Immunol.</u> , 1995, 102(3):635-641
	ABB	Knaus, P.I., et al., "A Dominant Inhibitory Mutant of the Type II Transforming Growth Factor $\beta$ Receptor in the Malignant Progression of a Cutaneous T-Cell Lymphoma," <u>Mol. Cell. Biology</u> , 1996, 16:3480-3489
	ACC	Langner, K.D., et al., "Antiviral Effects of Different CD4-Immunoglobulin Constructs Against HIV-1 and SIV: Immunological Characterization, Pharmacokinetic Data and In Vivo Experiments," <u>Arch. Virol.</u> , 1993, 130, 157-170
	ADD	Miller, Nicolas, et al., "Targeted vectors for gene therapy," <u>FASEB J.</u> , 1995, 9:190-199
	AEE	Miller, N., et al., "Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy," <u>Hum. Gene Ther.</u> , 1997, 8(7):803-815
	AFF	Mule, J.J., et al., "Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2," <u>Science</u> , 1984, 225:1487-1489
	AGG	Newell, K.A., et al., "Immunopotential of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens," <u>Ann. NY Acad. Sci.</u> , 1991, 636:279-287
	AHH	Ono, S., et al., "Rapid turnover of the CD3z chain independent of the TCR-CD3 complex in normal T cells," <u>Immunity</u> , 1995, 2:639-644
	AII	Pardoll, Drew M., "Editorial Overview," <u>Curr. Opin. Immunol.</u> , 1994, 6(5):705-706
	AJJ	Patten et al., "Transfer of Putative Complementarity - Determining Region Loops of T Cell Receptor V Domains Confers Toxin Reactivity but not Peptide/MHC Specificity," <u>J. Immunol.</u> , 1992, 150:2281-2294

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-416002	Application No. 10/756,818
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Stephen J. Russell et al.	
		Filing Date January 13, 2004	Group Art Unit 1646
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AKK	Rausch, D.M., et al., "CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro," <u>Biochem. Pharmacol.</u> , 1992, 43:1785-1796
	ALL	Rosenberg, S.A., et al., "A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes," <u>Science</u> , 1986, 233:1318-1321
	AMM	Ross, Gail, et al., "Gene Therapy in the United States: A Five-Year Status Report," <u>Human Gene Therapy</u> , 1996, 7:1781-1790
	ANN	Schultze, N., et al., "Efficient Control of gene expression by single step integration of the tetracycline system in transgenic mice," <u>Nature Biotechnology</u> , 1996, 14:499-503
	AOO	Shockett, P.E., et al., "Diverse strategies for tetracycline-regulated inducible gene expression.," <u>Proc. Natl. Acad. Sci. USA</u> , 1996, 93:5173-5176
	APP	Shockett, P.E., et al., "A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice," <u>Proc. Natl. Acad. Sci. USA</u> , 1995, 92:6522-6526
	AQQ	Spits, H., et al., "Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3," <u>Eur. J. Immunol.</u> , 1985, 15:88-91
	ARR	Stancovski, I., et al., "Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors," <u>J. Immunol.</u> , 1993, 151:6577-6582
	ASS	Szabo, B., et al., "Prevalence and specificity of lymphocytotoxic antibodies in different stages of HIV infection" <u>Acta. Virol.</u> , 1992, 36(4):392-400
	ATT	Taichman, R.S., et al., "A Strategy for Constructing Inducible Expression Plasmids for T-Lymphocytes," <u>Biotechniques</u> , 1993, 14:180-182
	AUU	Valitutti, S., et al., "Serial Triggering of Many T-Cell Receptors by a Few Peptide-MHC Complexes," <u>Nature</u> , 1995, 375:148-151
	AVV	Verma, I.M., et al., "Gene Therapy - Promises, Problems and Prospects," <u>Nature</u> , 1997, 389:239-242
	AWW	Watanabe, Mamoru, et al., "Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication," <u>Proc. Natl. Acad. Sci.</u> , 1991, 88:120-124
	AXX	Weissman, Allan M., et al., "Molecular Cloning and Chromosomal Localization of the Human T-Cell Receptor Chain: Distinction from the Molecular CD3 Complex," <u>Proc. Natl. Acad. Sci. USA</u> , 1988, 85:9709
	AYY	Yarranton, G.T., "Inducible Vectors for Expression in Mammalian Cells," <u>Curr. Opin. Biotechnol.</u> , 1992, 3:506-511

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	